MIRA
INFORM REPORT
|
Report Date : |
11.08.2008 |
IDENTIFICATION
DETAILS
|
Name : |
SUSUNG PHARM
CO., LTD. |
|
|
|
|
Registered Office : |
779-8, Wonsi-dong, Danwon-gu, Ansan-si, Gyeonggi-do, 425-852 |
|
|
|
|
Country : |
Korea |
|
|
|
|
Financials (as on) : |
31.12.2005 |
|
|
|
|
Date of Incorporation : |
11.22.1995 |
|
|
|
|
Com. Reg. No.: |
134-81-30150 |
|
|
|
|
Legal Form : |
Company Limited by Shares |
|
|
|
|
Line of Business : |
Manufacture of Medicinal Chemicals and Antibiotics |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Basic
|
Company
Name |
SUSUNG PHARM
CO., LTD. (Korean Company
Name : “수성약품”) |
|
Registered Address |
779-8, Wonsi-dong, Danwon-gu, Ansan-si,
Gyeonggi-do, Korea |
|
Zip Code |
425-852 |
|
Tel |
+82-31-491-6311~4 |
|
Fax |
+82-31-491-4797 |
|
E-mail |
gojwon@susung21.co.kr;yongkim88@empal.com |
|
Website |
www.susung21.co.kr |
|
Trading Address |
779-8, Wonsi-dong, Danwon-gu, Ansan-si,
Gyeonggi-do, Korea |
|
Tel |
+82-31-491-6311~4 |
|
Fax |
+82-31-491-4797 |
|
Type |
Import |
|
Industry |
Manufacture of Medicinal Chemicals and Antibiotics |
|
Main Business |
Ethanol |
|
Sub Business |
Wholesale of Pharmaceuticals |
|
Established (mm/dd/yyyy) |
11/22/1995 |
The Subject owns the
premises of registered HQ address.
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Alcohols or its substitutes(12352104) |
|
Sell |
Natural sugars or sweetening
products(50161509) |
|
Sell |
Famotidine(51171902) |
|
Sell |
Amines or imines or its
substitutes(12352116) |
|
Sell |
Ranitidine hydrochloride(51171904) |
|
Sell |
Acetaminophen(51142001) |
|
Sell |
Inorganic metal salts(12352302) |
|
Sell |
Clonixin Lysinate |
|
Sell |
L-Glutamic Acid HCl |
|
Sell |
Prednicarbate |
|
Sell |
Norfloxacin |
|
Buy |
Talc(11101518) |
|
Buy |
Natural sugars or sweetening
products(50161509) |
|
Buy |
Cereal flour(50221102) |
|
Buy |
Chemistry reagents or solutions(41116105) |
|
Buy |
Aliphatic and aromatic compounds(12352000) |
|
Buy |
Additives(12160000) |
|
Buy |
Inorganic acids(12352301) |
|
Sell |
Inorganic metal salts(12352302) |
|
Sell |
Calcium(11101511) |
CEO’s
|
Name |
Moon Soo-Yeon |
|
Address |
55-38, Yeokchon-dong, Eunpyeong-gu, Seoul, Korea |
|
Date of Birth |
11/04/1957 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Profiles
|
Capital |
1,800,000,000 KRW |
|
Employees |
24 |
|
Formation |
Co., Ltd by shares |
|
Bank Details |
Kook Bank-Ansan Branch |
|
Corporate Registered No. |
135011-0048930 |
|
Business Registered No. |
134-81-30150 |
|
Permit & Licenses |
05/23/1997 GMP Certificate 07/01/2001 BGMP Certificate Int’l Trade No.: 21024515 |
|
Shareholder Position |
N/A |
|
Company History |
11/22/1995 incorporated
as the present name 10/21/2002
Increased the authorized shares to 5,000,000 from 100,000 shares 10/29/2002
Increased 1,300,000,000 KRW from 1,600,000,000 KRW 11/20/2002
Increased capital to 1,800,000,000 KRW from 1,600,000,000 KRW |
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Day |
|
President & CEO |
Mr. |
Moon Soo-Yeon |
Male |
Korean |
05/20/2008 |
|
Director |
Mr. |
Jung Bong-Kwon |
Male |
Korean |
04/15/2003 |
|
Director |
Mr. |
Shin Sun-Young |
Male |
Korean |
05/20/2008 |
|
Auditor |
M/S. |
Shin Shin-Ja |
Female |
Korean |
12/30/2004 |
Financials
Unit: KRW
|
Year |
Sales |
Assets |
Net income |
|
|
|
|
|
|
2006 |
|
|
|
|
2005 |
6,628,000,000 |
4,224,000,000 |
72,000,000 |
|
2004 |
5,018,000,000 |
4,083,000,000 |
51,000,000 |
|
2003 |
3,166,000,000 |
|
|
Financial Description
Unit: KRW
|
Authorized
Capital |
50,000,000,000 |
|
Paid-Up
Capital |
1,800,000,000 |
|
Total Issues Shares |
180,000 |
Balance
Sheet
|
Unit : Million Korean Won |
As of 12/31/2005 |
As of 12/31/2004 |
As of 12/31/2003 |
|
Total Assets |
4,224 |
4,083 |
|
|
Current Assets |
2,591 |
2,414 |
|
|
-Quick Assets |
1,903 |
1,601 |
|
|
-Inventories |
688 |
813 |
|
|
Fixed Assets |
1,633 |
1,669 |
|
|
-Investment |
24 |
17 |
|
|
-Tangibles |
1,378 |
1,385 |
|
|
-Intangibles |
231 |
267 |
|
|
Total Liabilities |
2,323 |
2,255 |
|
|
Current Liabilities |
1,626 |
1,517 |
|
|
Fixed Liabilities |
697 |
738 |
|
|
Capital Stock |
1,800 |
1,800 |
|
|
Capital Surplus |
- |
- |
|
|
Profit Surplus |
100 |
31 |
|
|
Capital Adjustment |
- |
(-)3 |
|
|
Total Equity |
1,900 |
1,828 |
|
|
Liab. & Shareholder’s Equity |
4,224 |
4,083 |
|
Income
Statement
|
Unit : Million Korean Won |
As of 12/31/2005 |
As of 12/31/2004 |
As of 12/31/2003 |
|
Sales |
6,628 |
5,018 |
|
|
Cost of Sold Goods |
5,645 |
4,116 |
|
|
Gross Profit |
983 |
902 |
|
|
Selling & Admin. Expenses |
796 |
731 |
|
|
Operating Income |
187 |
171 |
|
|
Non-Operating Income |
8 |
6 |
|
|
Non-Operating expenses |
122 |
126 |
|
|
Ordinary Income |
72 |
51 |
|
|
Special Income |
- |
- |
|
|
Income Before Taxes |
72 |
51 |
|
|
Income Taxes Expenses |
- |
- |
|
|
Net Income |
72 |
51 |
|
Products, Technologies, Services
Description
|
Main
Products & Services |
-API -Nutraceuticals Conjugated Linoleic Acid Gamma Linoleic Acid Arachidonic Acid Co-Enzyme Q10 Alpha Lipoic Acid -Others Tacrolimus Teicoplanin |
Sales by
Region (Activity &
Markets)
The Subject imports from China and New Zealand.
Court
Action
Not Available.
News
Clipping
--
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.42.20 |
|
UK Pound |
1 |
Rs.81.48 |
|
Euro |
1 |
Rs.64.27 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)